These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38857952)

  • 21. Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants.
    Hammitt LL; Dagan R; Yuan Y; Baca Cots M; Bosheva M; Madhi SA; Muller WJ; Zar HJ; Brooks D; Grenham A; Wählby Hamrén U; Mankad VS; Ren P; Takas T; Abram ME; Leach A; Griffin MP; Villafana T;
    N Engl J Med; 2022 Mar; 386(9):837-846. PubMed ID: 35235726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short- and mid-term morbidity and primary-care burden due to infant respiratory syncytial virus infection: A Spanish 6-year population-based longitudinal study.
    Ares-Gómez S; Mallah N; Pardo-Seco J; Malvar-Pintos A; Pérez-Martínez O; Otero-Barrós MT; Súarez-Gaiche N; Santiago-Pérez MI; González-Pérez JM; López-Pérez LR; Rosón B; Alvárez-Gil RM; Ces-Ozores OM; Nartallo-Penas V; Mirás-Carballal S; Rodríguez-Tenreiro C; Rivero-Calle I; Salas A; Durán-Parrondo C; Martinón-Torres F
    Pediatr Allergy Immunol; 2024 May; 35(5):e14131. PubMed ID: 38700124
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hospitalization for bronchiolitis in children aged ≤ 1year, Southern Italy, year 2021: need for new preventive strategies?
    Baldassarre ME; Loconsole D; Centrone F; Caselli D; Martire B; Quartulli L; Acquafredda A; D'Amato G; Maffei G; Latorre G; Riganti A; Di Noia M; Chironna M; Laforgia N
    Ital J Pediatr; 2023 Jun; 49(1):66. PubMed ID: 37280662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of Respiratory Syncytial Virus Immunoprophylaxis in Reducing Bronchiolitis Hospitalizations Among High-Risk Infants.
    Wu P; Escobar GJ; Gebretsadik T; Carroll KN; Li SX; Walsh EM; Mitchel EF; Sloan C; Dupont WD; Yu C; Horner JR; Hartert TV
    Am J Epidemiol; 2018 Jul; 187(7):1490-1500. PubMed ID: 29351636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV).
    Bergeron HC; Tripp RA
    Expert Opin Investig Drugs; 2022 Jan; 31(1):23-29. PubMed ID: 34937485
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection.
    Brady T; Cayatte C; Roe TL; Speer SD; Ji H; Machiesky L; Zhang T; Wilkins D; Tuffy KM; Kelly EJ
    Front Immunol; 2023; 14():1283120. PubMed ID: 37901217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of antibody-based preventive alternatives for respiratory syncytial virus: a novel multi-criteria decision analysis framework and assessment of nirsevimab in Spain.
    Mestre-Ferrándiz J; Rivero A; Orrico-Sánchez A; Hidalgo Á; Abdalla F; Martín I; Álvarez J; García-Cenoz M; Del Carmen Pacheco M; Garcés-Sánchez M; Zozaya N; Ortiz-de-Lejarazu R
    BMC Infect Dis; 2024 Jan; 24(1):99. PubMed ID: 38238680
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory syncytial virus immunoprophylaxis in high-risk infants with heart disease.
    Alexander PM; Eastaugh L; Royle J; Daley AJ; Shekerdemian LS; Penny DJ
    J Paediatr Child Health; 2012 May; 48(5):395-401. PubMed ID: 22720323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for severe respiratory syncytial virus infection during the first year of life: development and validation of a clinical prediction model.
    Vartiainen P; Jukarainen S; Rhedin SA; Prinz A; Hartonen T; Vabalas A; Viippola E; Rodosthenous RS; Koskelainen S; Liu A; Lundholm C; Smew AI; Osvald EC; Helle E; Perola M; Almqvist C; Heinonen S; Ganna A
    Lancet Digit Health; 2023 Nov; 5(11):e821-e830. PubMed ID: 37890904
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Respiratory syncytial virus-associated hospitalizations among children: an Italian retrospective observational study.
    Fortunato F; Campanozzi A; Maffei G; Arena F; Carri VD; Rollo T; Lopalco PL; Martinelli D
    Ital J Pediatr; 2024 Mar; 50(1):45. PubMed ID: 38454523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiratory syncytial virus immunoprophylaxis in high-risk infants and development of childhood asthma.
    Carroll KN; Gebretsadik T; Escobar GJ; Wu P; Li SX; Walsh EM; Mitchel E; Sloan CD; Dupont WD; Hartert TV
    J Allergy Clin Immunol; 2017 Jan; 139(1):66-71.e3. PubMed ID: 27212083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis.
    Turalde-Mapili MWR; Mapili JAL; Turalde CWR; Pagcatipunan MR
    Front Pediatr; 2023; 11():1132740. PubMed ID: 37082704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Retrospective Cohort Study on Infant Respiratory Tract Infection Hospitalizations and Recurrent Wheeze and Asthma Risk: Impact of Respiratory Syncytial Virus.
    van Wijhe M; Johannesen CK; Simonsen L; Jørgensen IM; ; Fischer TK
    J Infect Dis; 2022 Aug; 226(Suppl 1):S55-S62. PubMed ID: 35426942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg.
    Ernst C; Bejko D; Gaasch L; Hannelas E; Kahn I; Pierron C; Del Lero N; Schalbar C; Do Carmo E; Kohnen M; Andlauer E; Hublart P; Masi S; de la Fuente Garcia I; Vergison A; Mossong J
    Euro Surveill; 2024 Jan; 29(4):. PubMed ID: 38275017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study.
    Nygaard U; Hartling UB; Nielsen J; Vestergaard LS; Dungu KHS; Nielsen JSA; Sellmer A; Matthesen AT; Kristensen K; Holm M
    Lancet Child Adolesc Health; 2023 Mar; 7(3):171-179. PubMed ID: 36634692
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023.
    Jones JM; Fleming-Dutra KE; Prill MM; Roper LE; Brooks O; Sánchez PJ; Kotton CN; Mahon BE; Meyer S; Long SS; McMorrow ML
    MMWR Morb Mortal Wkly Rep; 2023 Aug; 72(34):920-925. PubMed ID: 37616235
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Balanced on the Biggest Wave: Nirsevimab for Newborns.
    McPherson C; Lockowitz CR; Newland JG
    Neonatal Netw; 2024 Apr; 43(2):105-115. PubMed ID: 38599778
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of viral codetection in infants with respiratory syncytial virus bronchiolitis.
    Bernet Sánchez A; Bellés Bellés A; García González M; Minguell Domingo L; Solé Mir E
    Enferm Infecc Microbiol Clin (Engl Ed); 2024; 42(6):308-312. PubMed ID: 37468350
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.